Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Immunocore報告更新後的第一階段Brenetafusp數據顯示，Brenetafusp在單一療法和抗PD1聯合使用中具有良好的耐受性，並顯示出持久的臨床益處
Immunocore Reports Updated Phase 1 Brenetafusp Data Showing Brenetafusp Was Well Tolerated In Monotherapy And In Combination With Anti-PD1 And Demonstrated A Durable Clinical Benefit
Immunocore報告更新後的第一階段Brenetafusp數據顯示，Brenetafusp在單一療法和抗PD1聯合使用中具有良好的耐受性，並顯示出持久的臨床益處
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。